Subtyping of Group 3/4 medulloblastoma as a potential prognostic biomarker among patients treated with reduced dose of craniospinal irradiation: a Japanese Pediatric Molecular Neuro-Oncology Group study.
Fukuoka K, Kurihara J, Shofuda T, Kagawa N, Yamasaki K, Ando R, Ishida J, Kanamori M, Kawamura A, Park YS, Kiyotani C, Akai T, Keino D, Miyairi Y, Sasaki A, Hirato J, Inoue T, Nakazawa A, Koh K, Nishikawa R, Date I, Nagane M, Ichimura K, Kanemura Y.
Fukuoka K, et al. Among authors: kurihara j.
Acta Neuropathol Commun. 2023 Sep 25;11(1):153. doi: 10.1186/s40478-023-01652-4.
Acta Neuropathol Commun. 2023.
PMID: 37749662
Free PMC article.